Literature DB >> 22895019

Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats.

Jasmina Varagic1, Sarfaraz Ahmad, Jessica L Voncannon, Norihito Moniwa, Stephen W Simington, Bridget K Brosnihan, Patricia E Gallagher, Javad Habibi, James R Sowers, Carlos M Ferrario.   

Abstract

OBJECTIVES: Increased sympathetic outflow, renin-angiotensin system (RAS) activity, and oxidative stress are critical mechanisms underlying the adverse cardiovascular effects of dietary salt excess. Nebivolol is a third-generation, highly selective β1-receptor blocker with RAS-reducing effects and additional antioxidant properties. This study evaluated the hypothesis that nebivolol reduces salt-induced cardiac remodeling and dysfunction in spontaneous hypertensive rats (SHRs) by suppressing cardiac RAS and oxidative stress.
METHODS: Male SHRs (8 weeks of age) were given an 8% high salt diet (HSD; n = 22), whereas their age-matched controls (n = 10) received standard chow. In a subgroup of HSD rats (n = 11), nebivolol was given at a dose of 10 mg/kg per day by gastric gavage.
RESULTS: After 5 weeks, HSD exacerbated hypertension as well as increased left-ventricular weight and collagen deposition while impairing left-ventricular relaxation. Salt-induced cardiac remodeling and dysfunction were associated with increased plasma renin concentration (PRC), cardiac angiotensin II immunostaining, and angiotensin-converting enzyme (ACE)/ACE2 mRNA and activity ratio. HSD also increased cardiac 3-nitrotyrosine staining indicating enhanced oxidative stress. Nebivolol treatment did not alter the salt-induced increase in arterial pressure, left-ventricular weight, and cardiac dysfunction but reduced PRC, cardiac angiotensin II immunostaining, ACE/ACE2 ratio, oxidative stress, and fibrosis.
CONCLUSIONS: Our data suggest that nebivolol, in a blood pressure-independent manner, ameliorated cardiac oxidative stress and associated fibrosis in salt-loaded SHRs. The beneficial effects of nebivolol may be attributed, at least in part, to the decreased ACE/ACE2 ratio and consequent reduction of cardiac angiotensin II levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895019      PMCID: PMC3567851          DOI: 10.1097/HJH.0b013e328356766f

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  56 in total

Review 1.  The role of sodium in hypertension is more complex than simply elevating arterial pressure.

Authors:  Edward D Frohlich; Jasmina Varagic
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2004-11

2.  Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2005-12-19       Impact factor: 10.190

3.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.

Authors:  S S Gottlieb; R J McCarter; R A Vogel
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

4.  Antihypertensive response to prolonged tempol in the spontaneously hypertensive rat.

Authors:  William J Welch; Margarida Mendonca; Jonathan Blau; Alex Karber; Kathryn Dennehy; Kinjal Patel; Yuen-Sum Lao; Pedro A José; Christopher S Wilcox
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

5.  Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal.

Authors:  Estela I Guerrero; Noelia Ardanaz; María A Sevilla; Miguel A Arévalo; María J Montero
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

6.  Differential effects of isoproterenol on the activity of angiotensin-converting enzyme in the rat heart and aorta.

Authors:  V C Busatto; V Cunha; M A Cicilini; J G Mill
Journal:  Braz J Med Biol Res       Date:  1999-03       Impact factor: 2.590

7.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

8.  NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1.

Authors:  Ahmed A Elmarakby; E Dabbs Loomis; Jennifer S Pollock; David M Pollock
Journal:  Hypertension       Date:  2004-12-27       Impact factor: 10.190

9.  Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload.

Authors:  David J Grieve; Jonathan A Byrne; Anjana Siva; Joanne Layland; Sofian Johar; Alison C Cave; Ajay M Shah
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

10.  Dietary-sodium-induced cardiac remodeling in spontaneously hypertensive rat versus Wistar-Kyoto rat.

Authors:  F H Leenen; B Yuan
Journal:  J Hypertens       Date:  1998-06       Impact factor: 4.844

View more
  13 in total

1.  Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure.

Authors:  Ibrahim N Mansour; Adam P Bress; Vicki Groo; Sahar Ismail; Grace Wu; Shitalben R Patel; Julio D Duarte; Rick A Kittles; Thomas D Stamos; Larisa H Cavallari
Journal:  J Card Fail       Date:  2015-12-22       Impact factor: 5.712

2.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

Review 3.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 4.  Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.

Authors:  Jasmina Varagic; Henry Punzi; Carlos M Ferrario
Journal:  Integr Blood Press Control       Date:  2014-11-26

5.  Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion.

Authors:  Ji Young Hong; So Yeong Park; Youngmi Kim; Chang Youl Lee; Myung Goo Lee
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

6.  Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.

Authors:  Julieta S Del Mauro; Paula D Prince; Yanina Santander Plantamura; Miguel A Allo; Luciano Parola; Nahuel Fernandez Machulsky; Marcela A Morettón; Eliana P Bin; Germán E González; Facundo M Bertera; Andrea Carranza; Gabriela Berg; Carlos A Taira; Martín Donato; Diego A Chiappetta; Ariel H Polizio; Christian Höcht
Journal:  Hypertens Res       Date:  2021-02-22       Impact factor: 3.872

7.  Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.

Authors:  Bingong Li; Jian Xiao; Yong Li; Jian Zhang; Minghui Zeng
Journal:  Exp Ther Med       Date:  2013-08-27       Impact factor: 2.447

Review 8.  From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.

Authors:  Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell
Journal:  Front Physiol       Date:  2014-06-24       Impact factor: 4.566

9.  High-salt intake suppressed microRNA-133a expression in Dahl SS rat myocardium.

Authors:  Tong-Shuai Guo; Jie Zhang; Jian-Jun Mu; Fu-Qiang Liu; Zu-Yi Yuan; Ke-Yu Ren; Dan Wang
Journal:  Int J Mol Sci       Date:  2014-06-16       Impact factor: 5.923

10.  Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis.

Authors:  Jie Yang; Fei Xiang; Peng-Cheng Cai; Yu-Zhi Lu; Xiao-Xiao Xu; Fan Yu; Feng-Zhi Li; Peter A Greer; Huan-Zhong Shi; Qiong Zhou; Jian-Bao Xin; Hong Ye; Yunchao Su; Wan-Li Ma
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-03       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.